CYPRESS SEMICONDUCTOR CORP /DE/ Form 10-Q May 02, 2014 <u>Tables of Contents</u>

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
У	OF 1934

For the quarterly period ended March 30, 2014 OR

.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 1-10079

CYPRESS SEMICONDUCTOR CORPORATION (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 198 Champion Court, San Jose, California 95134 (Address of principal executive offices and zip code) (408) 943-2600 (Registrant's telephone number, including area code) 94-2885898 (I.R.S. Employer Identification No.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \circ No "Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes \circ No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ý Accelerated filer " Non-accelerated filer " (Do not check if a smaller reporting company) Smaller reporting company " Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes " No ý The total number of outstanding shares of the registrant's common stock as of April 27, 2014 was 157,724,443

INDEX

		Page
<u>PART I-</u>	<u>—FINANCIAL INFORMATIO</u> N	
Forward	-Looking Statements	<u>2</u>
Item 1. Item 2. Item 3. Item 4.	<u>Financial Statements</u> (unaudited) <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> <u>Quantitative and Qualitative Disclosures about Market Risk</u> <u>Controls and Procedures</u>	<u>3</u> <u>26</u> <u>34</u> <u>34</u>
<u>PART II</u>	<u>—OTHER INFORMATION</u>	
Item 1.	Legal Proceedings	<u>35</u>
Item 1A.	Risk Factors	<u>35</u>
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	<u>35</u>
Item 3.	Defaults Upon Senior Securities	<u>35</u> <u>35</u> <u>35</u> <u>35</u> <u>35</u>
Item 4.	Mine Safety Disclosures	<u>35</u>
Item 5.	Other Information	<u>36</u>
Item 6.	Exhibits	<u>37</u>
	Signatures	<u>36</u> <u>37</u> <u>38</u>

PART I-FINANCIAL INFORMATION

Forward-Looking Statements

The discussion in this Quarterly Report on Form 10-Q contains statements that are not historical in nature, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, , that involve risks and uncertainties, including, but not limited to, statements related to our external wafer foundry partners and our expectation that our business will increase with them in the future, our beliefs regarding our flexible manufacturing initiative, our expectation regarding future dividend payments and stock repurchases, the increasing complexity we expect in our product design, our expectations that we will continue to enter into additional licensing arrangements in the future, our expectations regarding the timing and cost of our restructuring liabilities, expected purchases by IV, our expectations, beliefs and strategies regarding our active litigation matters, including our intent to defend or pursue those matters rigorously; the competitive advantage we believe we have with our patents as well as our proprietary programmable technologies and programmable products, our expectation that we will continue to make significant investments in our current business ventures as well as new ventures, our belief in backlog as an indicator of future revenue, the future potential impact of environmental regulations that may impact our business, our ability to compete in our highly competitive industry and markets in the future, our expectation that our revenue from the distribution channel (as a percentage of our overall sales) will increase in the future, the risk associated with our yield investment agreements, our foreign currency exposure and the impact exchange rates could have on our operating margins, the adequacy of our cash, working capital positions and borrowing arrangements to provide sufficient liquidity and capital needs of the Company, our expectations regarding our pending appeal of our recently completed India tax audit as well as our Philippines tax audit, our ability to recognize certain unrecognized tax benefits within the next twelve months and the events that could impact such tax benefits, our future investment strategy, our expectation that we will continue to investigate strategic acquisition and investment transactions, the impact of interest rate fluctuations on our investments, the volatility of our stock price, the adequacy of our real estate properties, the utility of our non-GAAP reporting, the adequacy of our audits, our expectations regarding our 2011 restructuring activities, the potential impact of or possible payments due under our indemnification obligations and the impact of new accounting standards on our financial statements. We use words such as "plan," "anticipate," "believe," "expect," "future," "intend" and similar expressions to identi forward-looking statements. Such forward-looking statements are made as of the date hereof and are based on our current expectations, beliefs and intentions regarding future events or our financial performance and the information available to management as of the date hereof. Except as required by law, we assume no responsibility to update any such forward-looking statements. Our actual results could differ materially from those expected, discussed or projected in the forward-looking statements contained in this Annual Report on Form 10-K for any number of reasons, including, but not limited to, the state and future of the general economy and its impact on the markets and consumers we serve and our investments; our ability to timely deliver our proprietary and programmable technologies and products, the current credit conditions; our ability to expand our customer base, our ability to transform our business with a leading portfolio of programmable products; the number and nature of our competitors; the changing environment and/or cycles of the semiconductor industry; foreign currency exchange rates; our ability to efficiently manage our manufacturing facilities and achieve our cost goals emanating from our flexible manufacturing strategy; our ability to achieve our goals related to our restructuring activities; our success in our pending litigation matters, our ability to manage our investments and interest rate and exchange rate exposure; changes in the law, the results of our pending tax examinations; our ability to achieve liquidity in our investments, the failure or success of our Emerging Technology division and/or the materialization of one or more of the risks set forth above or in Item 1A (Risk Factors) in this Quarterly Report on Form 10-Q and in Part I, Item 1A (Risk Factors) in our Annual Report on Form 10-K for the fiscal year ended December 29, 2013.

ITEM 1. FINANCIAL STATEMENTS CYPRESS SEMICONDUCTOR CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

(Unaudited)	March 30, 2014 (In thousands, per-share amou	-	
ASSETS			
Current assets:			
Cash and cash equivalents	\$103,644	\$86,009	
Short-term investments	7,881	18,453	
Accounts receivable, net	118,215	81,084	
Inventories	89,193	100,612	
Other current assets	24,494	33,555	
Total current assets	343,427	319,713	
Property, plant and equipment, net	253,234	258,585	
Goodwill	65,696	65,696	
Intangible assets, net	38,982	40,828	
Other long-term assets	79,568	78,062	
Total assets	\$780,907	\$762,884	
LIABILITIES AND EQUITY			
Current liabilities:			
Accounts payable	\$49,940	\$47,893	
Accrued compensation and employee benefits	37,053	38,972	
Deferred margin on sales to distributors	141,669	122,578	
Dividends payable	17,263	16,850	
Income taxes payable	2,874	3,034	
Other current liabilities	82,246	76,515	
Total current liabilities	331,045	305,842	
Other tax liabilities	21,177	26,831	
Long-term revolving credit facility	227,000	227,000	
Other long-term liabilities	25,339	27,528	
Total liabilities	604,561	587,201	
Commitments and contingencies (Note 8)		, -	
Equity:			
Preferred stock, \$.01 par value, 5,000 shares authorized; none issued and outstanding		_	
Common stock, \$.01 par value, 650,000 and 650,000 shares authorized; 300,119 and			
296,346 shares issued; 156,970 and 153,214 shares outstanding at March 30, 2014	3,001	2,963	
and December 29, 2013, respectively	,		
Additional paid-in-capital	2,675,102	2,665,453	
Accumulated other comprehensive loss) (177)	
Accumulated deficit) (397,849)	
Stockholders' equity before treasury stock	2,272,139	2,270,390	
Less: shares of common stock held in treasury, at cost; 143,149 and 143,132 shares at			
March 30, 2014 and December 29, 2013, respectively	(2,090,420) (2,090,233)	
Total Cypress stockholders' equity	181,719	180,157	
Noncontrolling interest	,) (4,474)	
Total equity	176,346	175,683	
······································	,	,	

Total liabilities and equity\$780,907\$762,884The accompanying notes are an integral part of these condensed consolidated financial statements.\$762,884

CYPRESS SEMICONDUCTOR CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended			
	March 30, March 31		March 31,	
	2014		2013	
	(In thousands	, e	xcept per-sha	are
	amounts)			
Revenues	\$170,283		\$172,728	
Costs and expenses:				
Cost of revenues	92,561		93,682	
Research and development	45,330		49,330	
Selling, general and administrative	42,609		45,442	
Amortization of acquisition-related intangible assets	1,833		2,009	
Restructuring costs	(1,014)	11,440	
Total costs and expenses	181,319		201,903	
Operating loss	(11,036)	(29,175)
Interest and other income (expense), net	(1,750)	199	
Loss before income taxes and noncontrolling interest	(12,786)	(28,976)
Income tax provision (benefit)	(4,517)	146	
Net loss	(8,269)	(29,122)
Adjust for net loss attributable to noncontrolling interest	335		643	
Net loss attributable to Cypress	\$(7,934)	\$(28,479)
Net loss per share attributable to Cypress:				
Basic	\$(0.05)	\$(0.20)
Diluted	\$(0.05)	\$(0.20)
Cash dividend declared per share	\$0.11		\$0.11	
Shares used in net loss per share calculation:				
Basic	154,572		145,689	
Diluted	154,572		145,689	
The accompanying notes are an integral part of these condensed consolidated financi	al statements.			

CYPRESS SEMICONDUCTOR CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)

	Three Months Ended			
	March 30,		March 31,	
	2014		2013	
	(In thousands	s)		
Net loss	(8,269)	\$(29,122)
Available for sale investments:				
Change in net unrealized gains, net of tax benefit	(5)	1,264	
Net gains reclassified into earnings, net of tax effects			(16)
Other comprehensive income (loss)	(5)	1,248	
Comprehensive income (loss)	(8,274)	(27,874)
Comprehensive loss attributable to noncontrolling interest	335		643	
Comprehensive loss attributable to Cypress	\$(7,939)	\$(27,231)
The accompanying notes are an integral part of these condensed consolidated finance	ial statements.			

CYPRESS SEMICONDUCTOR CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Three Months March 30, 2014 (In thousands		Ended March 31, 2013	
Cash flows from operating activities:	¢ (7.004	``	¢ (2 0, 17 0)	``
Net loss	\$(7,934)	\$(28,479)
Adjustments to reconcile net loss to net cash provided by operating activities:	16.000		10 107	
Stock-based compensation expense	16,823		12,437	
Depreciation and amortization	11,431	``	12,594	、 、
Deferred income taxes and other tax liabilities	(5,682		(2,066)
Restructuring costs	(298)	11,440	
(Gain) Loss on sale or retirement of property and equipment, net	(579)	262	
Other	713		(267)
Changes in operating assets and liabilities:				
Accounts receivable, net	(37,132)	(49,720)
Inventories	12,219		17,952	
Other current and long-term assets	12,549		1,396	
Accounts payable and other liabilities	3,989		(3,503)
Deferred margin on sales to distributors	19,092		36,219	
Net cash provided by operating activities	25,191		8,265	
Cash flows from investing activities:				
Proceeds from sales or maturities of available-for-sale investments	10,450		34,284	
Purchases of available-for-sale investments			(23,717)
Net employee contributions to (distribution of) deferred compensation plan	(1,144)	(1,447)
Acquisition of property, plant and equipment	(5,599)	(9,298)
Cash paid for equity investments	(5,000)	(861)
Proceeds from sale of held-for-sale equipment	3,240			
Other	116		144	
Net cash provided by (used in) investing activities	2,063		(895)
Cash flows from financing activities:				
Withholding of common shares for tax obligations on vested restricted shares	(186)	(4,321)
Payment of dividends	(16,850)	(15,845)
Issuance of common shares under employee stock plan	8,764		11,560	
Repayment of equipment leases and loans, net	(1,347)	(4,748)
Net cash provided used in financing activities	(9,619		(13,354)
Net increase (decrease) in cash and cash equivalents	17,635		(5,984)
Cash and cash equivalents, beginning of period	86,009		63,203	<i>.</i>
Cash and cash equivalents, end of period	\$103,644		\$57,219	
The accompanying notes are an integral part of these condensed consolidated finance			·	

Tables of Contents

CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Fiscal Years Cypress Semiconductor Corporation ("Cypress" or the "Company") reports on a fiscal-year basis. The Company ends its quarters on the Sunday closest to the end of the applicable calendar quarter except in a 53-week fiscal year, in which

quarters on the Sunday closest to the end of the applicable calendar quarter, except in a 53-week fiscal year, in which case the additional week falls into the fourth quarter of that fiscal year. Fiscal 2014 and fiscal 2013 had 52 weeks. The first quarter of fiscal 2014 ended on March 30, 2014 and the first quarter of fiscal 2013 ended on March 31, 2013.

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal, recurring items, which are necessary to state fairly the financial information included therein. The financial data should be read in conjunction with the audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 29, 2013.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Certain prior period balances have been reclassified to conform to the current year presentation.

The condensed consolidated results of operations for the three months ended March 30, 2014 are not necessarily indicative of the results to be expected for the full fiscal year.

During the three months ended March 30, 2014, the Company recorded an out-of-period correcting adjustment to write off certain manufacturing and subcontractor costs that were capitalized within other current assets in previous periods. This correction resulted in an increase to the Company's net loss of \$2.6 million for the three months ended March 30, 2014. The Company recorded these corrections, in the aggregate totaling \$2.6 million, in cost of revenues in the three months ended March 30, 2014. Management assessed the impact of these errors and concluded that the amounts were not material, either individually or in the aggregate, to any prior period and to the Q1 2014 interim or expected full year financial statements.

Change in Accounting Principle

During the first quarter of fiscal 2014, we increased our ownership in a privately-held entity which required us to change from the cost method of accounting to the equity method of accounting for this investment. Under the equity method of accounting, we are required to record our interest in the company's reported net income or loss each reporting period. Additionally, we are required to present our prior period financial results to reflect the equity method of accounting from the date of the initial investment in the company which resulted in an adjustment to retained earnings and a corresponding reduction to our investment. See Note 9 for more information. Recent Accounting Pronouncements

In July 2013, the FASB issued an ASU on Income Taxes, to improve the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is expected to reduce diversity in practice and is expected to better reflect the manner in which an entity would settle at the reporting date any additional income taxes that would result from the disallowance of a tax position when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exist. This guidance is effective for our interim and annual periods beginning after December 15, 2013. We adopted this guidance in the first quarter of fiscal 2014 and our adoption did not have a significant impact on our condensed consolidated financial statements. See Note 13 for more information.

NOTE 2. GOODWILL AND INTANGIBLE ASSETS

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The carrying amount of goodwill at March 30, 2014 and at December 29, 2013 was \$65.7 million, of which \$33.9 million was in MPD and \$31.8 million was in PSD.

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

The following table presents details of our intangible assets:

	As of March 30, 2014			As of Decem	ıber 29, 2013
	Gross	Accumulated Amortization	Net	Gross	Accumulated Amortization Net
	(In thousand	s)			
Acquisition-related intangible assets	\$151,773	\$(113,507) \$38,266	\$151,773	\$(111,673) \$40,100
Non-acquisition related intangible assets	10,523	(9,807) 716	10,423	(9,695) 728
Total intangible assets	\$162,296	\$(123,314)) \$38,982	\$162,196	\$(121,368) \$40,828
As of March 30, 2014, the estim	ated future an	ortization exp	bense of these in	ntangible asset	s was as follows:

	(In thousands)
2014	5,168
2015	5,620
2016	5,221
2017	5,221
2018 and future	17,752
Total future amortization expense	\$38,982

NOTE 3. RESTRUCTURING

For the three months ended March 30, 2014 we recorded a benefit arising from restructuring related items of \$(1.0) million, compared to a restructuring charge of \$11.4 million incurred during the three months ended March 31, 2013. The benefit for the period primarily resulted from the gain on the sale of a previously restructured asset. The determination of when we accrue for severance and benefits costs, and which accounting standard applies, depends on whether the termination benefits are provided under a one-time benefit arrangement or under an on-going benefit arrangement.

The following table summarizes the restructuring charges recorded in the Condensed Consolidated Statements of Operations:

	Three Months Ende	d
	March 30,	March 31,
	2014	2013
	(In thousands)	
Personnel costs	\$(154) \$4,157
Impairment of property, plant and equipment	—	6,698
Other	(281) 585
Gain on sale of held-for-sale assets	(579) —
Total restructuring charges	\$(1,014) \$11,440

A summary of the restructuring activities related to personnel costs, which are primarily in the U.S. is summarized as follows:

<u>Table of Contents</u> CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

	(In thousa	nds)
Balance as of December 29 2013	\$4,158	
Provision (release)	(154)
Cash payments	(1,311)
Balance as of March 30, 2014	2,693	

The restructuring liability as of March 30, 2014 related primarily to personnel costs and is expected to be paid out within the next twelve months.

During fiscal 2013, we implemented a restructuring plan to reduce operating expenses as part of our 2013 corporate priorities. The plan included the termination of employees and the disposal of certain equipment located in our Bloomington, Minnesota facility. During the first quarter of fiscal 2014, we did not record any new restructuring charges. For the first fiscal quarter of 2013, we recorded restructuring charges of \$11.0 million related to the Fiscal 2013 Restructuring Plan of which \$6.7 million was related to property, plant and equipment, \$3.8 million was related to personnel costs and \$0.5 million was mainly related to the amounts payable upon the termination of agreements with certain distributor representatives.

During the first quarter of fiscal 2014, we did not record any new restructuring charges under a restructuring plan which we first announced in fiscal 2011 ("Fiscal 2011/2012 Restructuring Plan"). This plan allowed us to continue to allocate and align our resources to the business units that we expect will drive future development and revenue growth. For the first fiscal quarter of 2013, we recorded restructuring charges of \$0.4 million. Assets Held-For-Sale

During the first quarter of 2013, we incurred a \$6.0 million charge to write down certain equipment to the then-current fair value of \$2.3 million. The net book value of these assets was classified as held-for-sale and included in "Other current assets" in the Condensed Consolidated Balance Sheet as of December 29, 2013. In the first fiscal quarter of 2014, we sold this equipment and recorded a gain on the sale of nearly \$0.6 million, net of selling costs, as a credit to restructuring costs in the Condensed Consolidated Statement of Operations.

NOTE 4. BALANCE SHEET COMPONENTS

Accounts Receivable, Net

	As of March 30, 2014 (In thousands)	December 29, 2013
Accounts receivable, gross Allowance for doubtful accounts receivable and sales returns Total accounts receivable, net	\$ 121,585 (3,370 \$ 118,215	\$84,431) (3,347) \$81,084
Inventories		
	As of	

Raw materials Work-in-process Finished goods Total inventories Other Current Assets

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

	As of	
	March 30,	December 29,
	2014	2013
	(In thousands)	
Prepaid expenses	\$18,224	\$26,364
Assets held-for-sale		2,260
Other current assets	6,270	4,931
Total other current assets	\$24,494	\$33,555
Other Long-term Assets		

	March 30,	December 29,
	2014	2013
	(In thousands)	
Employee deferred compensation plan	\$42,141	\$42,351
Investments:		
Equity securities	19,040	15,009
Other assets	18,387	20,702
Total other long-term assets	\$79,568	\$78,062
Other Current Liabilities		

As of

	As of	
	March 30,	December 29,
	2014	2013
	(In thousands)
Employee deferred compensation plan	\$42,200	\$41,582
Restructuring accrual (see Note 3)	2,693	4,158
Capital lease-current portion (see Note 8)	2,722	2,659
Equipment loan-current portion (see Note 10)	2,127	2,825
Rebate reserve-current portion	10,731	2,445
Other current liabilities	21,773	22,846
Total other current liabilities	\$82,246	\$76,515

Other Long-term L	Liabilities
-------------------	-------------

	As of	
	March 30,	December 29,
	2014	2013
	(In thousands)	
Equipment loan-long-term portion (see Note 10)	\$5,918	\$5,918
Capital lease-long-term portion (see Note 8)	9,106	9,828
Other long-term liabilities	10,315	11,782
Total other long-term liabilities	\$25,339	\$27,528

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

NOTE 5. FAIR VALUE MEASUREMENTS

Assets/Liabilities Measured at Fair Value on a Recurring Basis

The following tables present the fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis and our non-financial assets measured at fair value on a non-recurring basis:

	As of Mare Level 1 (In thousan	ch 30, 2014 Level 2 nds)	Level 3	Total	As of Dece Level 1	ember 29, 20 Level 2	013 Level 3	Total
Financial Assets								
Cash equivalents:								
Money market funds	\$9,249	\$—	\$—	\$9,249	\$29,719	\$—	\$—	\$29,719
Commercial paper	—	11,000		11,000		—	—	
Total cash equivalents		11,000		20,249	29,719		—	29,719
Short-term investments	S:							
Corporate notes and bonds	—	7,014		7,014	—	14,677	_	14,677
Commercial paper	_	_	_			1,300	_	1,300
Certificates of deposit	_	867		867		2,476	_	2,476
Non-financial assets						2,260		2,260
held-for-sale						2,200	—	2,200
Total short-term		7,881		7,881		20,713		20,713
investments		7,001		7,001		20,715		20,715
Employee deferred								
compensation plan								
assets:								
Cash equivalents	3,548		—	3,548	3,941	—	—	3,941
Mutual funds	22,778		—	22,778	23,415	—	—	23,415
Equity securities	8,546	—	—	8,546	7,977		—	7,977
Fixed income	3,416			3,416	3,192		—	3,192
Money market funds		3,853		3,853	4,080		—	4,080
Total employee								
deferred compensation	38,288	3,853		42,141	42,605		—	42,605
plan assets								
Total financial assets	\$47,537	\$22,734	\$—	\$70,271	\$72,324	\$20,713	\$—	\$93,037
Financial Liabilities								
Employee deferred								
compensation plan	\$—	\$42,200	\$—	\$42,200	\$—	\$41,582	\$—	\$41,582
liability								

Valuation Techniques:

There have been no changes to our valuation techniques used to measure our assets and liabilities. For a description of our valuation techniques, refer to our Form 10-K for the year ended December 29, 2013.

Assets Measured at Fair Value on a Nonrecurring Basis

As of March 30, 2014, the carrying value of our line of credit was \$227.0 million. The fair value of our line of credit approximates its fair value since it bears interest rates that are similar to existing market rates that would be offered to the Company and represents a Level 2 measurement.

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

Investments in Equity Securities

Our investments in equity securities include long-term investments in non-marketable equity securities of mainly privately-held companies of approximately \$19.1 million and \$15.0 million as of March 30, 2014 and December 29, 2013, respectively.

Included in our non-marketable equity securities is our investment in a company that designs, develops and manufactures products in the area of advanced battery storage for mobile consumer devices. In February 2012, we entered into a Stock Purchase Agreement (the "Agreement") with that company and through the end of fiscal 2013, we have cumulatively invested \$13.5 million in that company. During the first quarter of fiscal 2014, we invested an additional \$4.0 million. As of March 30, 2014, we own approximately 20.3% of the company's outstanding voting shares and thus began to use the equity accounting method for this investment. As of March 30, 2014, our investment in this company, after the impact of equity accounting, was \$13.6 million and is recorded as part of our investments in non-marketable securities. Subject to the attainment of certain milestones, we plan to purchase additional preferred stock up to approximately \$19.1 million in fiscal 2014. If our future commitments are fully funded, we could become their majority shareholder and consolidate the financial results of this company. See Note 9 for additional disclosure related to the equity accounting method for this investment.

The remaining privately-held equity investments are accounted for under the cost method and are periodically reviewed for other-than-temporary declines in fair value.

There were no significant transfers between Level 1, Level 2 and Level 3 fair value hierarchies during the three months ended March 30, 2014.

NOTE 6. INVESTMENTS AND EMPLOYEE DEFERRED COMPENSATION PLAN Available-For-Sale Securities

The following tables summarize our available-for-sale and other investments:

	As of Mar	ch 30, 2014			As of Dece	ember 29, 20	013	
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
	(In thousan	nds)						
Reported as cash equivalents:								
Money market funds	\$9,249	\$—	\$—	\$9,249	\$29,719	\$—	\$—	\$29,719
Commercial paper	11,000			11,000		_		
Total cash equivalents	20,249			20,249	29,719	_	_	29,719
Reported as short-term investments:								
Corporate note and bonds	7,009	5	_	7,014	14,667	10	_	14,677
Federal agency		_	_		_	_		_
Commercial paper			—		1,300	—		1,300
Certificates of deposit	867	_	_	867	2,476			2,476
Assets held-for-sale		_	_		_	_	_	
Total short-term investments	7,876	5		7,881	18,443	10		18,453
	\$28,125	\$5	\$—	\$28,130	\$48,162	\$10	\$—	\$48,172

Total available-for-sale securities and other investments

As of March 30, 2014, the contractual maturities of our available-for-sale investments and certificates of deposit were as follows (the table below does not include our investments in marketable equity securities and our assets held-for-sale):

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

	Cost	Fair Value
	(in thousands)	
Maturing within one year	\$28,125	\$28,130
Maturing in one to three years		
Maturing in more than three years		
Total	\$28,125	\$28,130
Papizzad gains from salas and losses of available for sala investments during the thr	a months and ad	March 30 2014

Realized gains from sales and losses of available-for-sale investments during the three months ended March 30, 2014 and March 31, 2013 were not material.

Employee Deferred Compensation Plan

We have a deferred compensation plan which provides certain key employees, including our executive management, with the ability to defer the receipt of compensation in order to accumulate funds for retirement on a tax-deferred basis. We do not make contributions to the deferred compensation plan or guarantee returns on the investments. Participant deferrals and investment gains and losses remain as our liabilities and the underlying assets are subject to claims of general creditors.

Under the deferred compensation plan, the assets are recorded at fair value in each reporting period with the offset being recorded in "Interest and other income, net." The liabilities are recorded at fair value in each reporting period with the offset being recorded as an operating expense or income. As of March 30, 2014 and December 29, 2013, the fair value of the assets was \$42.1 million and \$42.4 million, respectively, and the fair value of the liabilities was \$42.2 million and \$41.6 million, respectively.

All non-cash expense and income recorded under the deferred compensation plan are included in the following line items in the Condensed Consolidated Statements of Operations:

	Three Months Ended		
	March 30,	March 31,	
	2014	2013	
	(In thousands))	
Changes in fair value of assets recorded in:			
Interest and other income, net	\$859	\$2,424	
Changes in fair value of liabilities recorded in:			
Cost of revenues	(218) (422)
Research and development expenses	(424) (815)
Selling, general and administrative expenses	(964) (1,861)
Total income (expense)	\$(747) \$(674)

NOTE 7. STOCK-BASED COMPENSATION

Our equity incentive plans are broad-based, long-term programs intended to attract and retain talented employees and align stockholder and employee interests.

The following table summarizes the stock-based compensation expense, by line item recorded in the Condensed Consolidated Statements of Operations:

 Marce Months ended

 March 30,
 March 31,

 2014
 2013

 (In thousands)
 \$3,618

Cost of revenues

Research and development	7,183	4,967
Selling, general and administrative	7,389	3,852
Total stock-based compensation	\$16,823	\$12,437

As stock-based compensation expense recognized in the Condensed Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The accounting guidance requires forfeitures

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Cash proceeds from the issuance of shares under the employee stock plans were approximately \$8.8 million for the three months ended March 30, 2014 and \$11.6 million and for the three months ended March 31, 2013. We did not recognize a tax benefit from stock option exercises for the three months ended March 30, 2014 or March 31, 2013. As of March 30, 2014 and December 29, 2013, stock-based compensation capitalized in inventories totaled \$6.0 million and \$5.3 million, respectively.

The following table summarizes the stock-based compensation expense by type of awards:

	Three Months Ended		
	March 30,	March 31,	
	2014	2013	
	(In thousands)		
Stock options	\$1,449	\$2,521	
Restricted stock units and restricted stock awards	14,372	5,103	
Employee Stock Purchase Plan ("ESPP")	1,002	4,813	
Total stock-based compensation expense	\$16,823	\$12,437	
The following table summarizes the unrecognized stock based compensation expense	net of estimate	d forfaituras	h

The following table summarizes the unrecognized stock-based compensation expense, net of estimated forfeitures, by type of awards:

	As of	
		Weighted-
	March 30,	Average
	2014	Amortization
		Period
	(In thousands)	(In years)
Stock options	\$10,042	1.98
Restricted stock units and restricted stock awards	21,841	1.59
ESPP	2,293	0.57
Total unrecognized stock-based compensation balance	\$34,176	1.64
Valuation Assumptions		

We estimated the fair value of the stock options and ESPP awards using the Black-Scholes valuation model with the following assumptions:

	Three Months Ended	
	March 30, 2014	March 31, 2013
Expected life	0.5-7.27 years	0.5-7.27 years
Volatility	31.03%-37.96%	38.4%-46.3%
Risk-free interest rate	0.09%-1.73%	0.11%-0.84%
Dividend yield	4.1%	4.2%
The fair value of the restricted stock units and the restricted stock awards was ba	ased on our stock prio	ce on the date of
grant.		
Equity Incentive Program		

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

As of March 30, 2014, approximately 4.5 million stock options or 2.4 million restricted stock units and restricted stock awards were available for grant under the Amended and Restated 2013 Stock Plan and the 2012 Incentive Award Plan.

Stock Options:

The following table summarizes our stock option activities:

	Shares	Weighted- Average Exercise Price Per Share		
	(In thousands,	thousands, except r-share amounts)		
	per-share amo			
Options outstanding as of December 29, 2013	19,060	\$8.33		
Granted	141	\$10.03		
Exercised	(401	\$5.59		
Forfeited or expired	(289	\$11.93		
Options outstanding as of March 30, 2014	18,511	\$8.35		

The weighted-average grant-date fair value of the options granted during the three months ended March 30, 2014 was \$2.26. The weighted-average grant-date fair value of the options granted during the three months ended March 31, 2013 was \$2.35.

The aggregate intrinsic value of the options outstanding and options exercisable as of March 30, 2014 was approximately \$53.3 million and \$52.9 million, respectively. The aggregate intrinsic value represents the total pre-tax intrinsic value which would have been received by the option holders had all option holders exercised their options as of March 30, 2014 and does not include substantial tax payments.

The aggregate pre-tax intrinsic value of option exercises, which represents the difference between the exercise price and the value of Cypress common stock at the time of exercise, was \$1.9 million during the three months ended March 30, 2014, and \$6.0 million during the three months ended March 31, 2013.

The total number of exercisable in-the-money options was approximately 9.6 million shares as of March 30, 2014. As of March 30, 2014, stock options vested and expected to vest totaled approximately 17.7 million shares, with a weighted-average remaining contractual life of 4.2 years and a weighted-average exercise price of \$8.20 per share. Restricted Stock Units and Restricted Stock Awards

The following table summarizes our restricted stock unit and restricted stock award activities:

Service-based Restricted Stock Units and Awards	¹ Performance-base Restricted Stock Units	ed Shares	Weighted- Average Grant Date Fair Value Per Share
	· •		
4,055	4,597	8,652	\$11.97
394	3,239	3,633	\$10.03
(311)	(2,342)	(2,653) \$9.99
	Restricted Stock Units and Awards (In thousands per-share amo 4,055 394	RestrictedRestricted StockStock UnitsRestricted Stockand AwardsUnits(In thousands, exceptper-share amounts)4,0554,5973943,239	Restricted Stock UnitsPerformance-based Restricted StockStock UnitsRestricted StockShares Units(In thousands, except per-share amounts)4,0554,5978,6523943,2393,633

Walahad

Edgar Filing: CYPRESS SEMICONDUCTOR CORP /DE/ - Form 10-QForfeited(117) (1,750) (1,867) \$11.12Balance as of March 30, 20144,0223,7437,765\$11.54The 7.8 million outstanding restricted stock units and awards as of March 30, 2014 included approximately 3.2

million of performance-based restricted stock units and awards as of March 50, 2014 included approximately 5.2 million of performance-based restricted stock units ("PARS"). These PARS were issued to certain senior-level employees in the first quarter of fiscal 2014 and can be earned ratably over a period of one to two years, subject to the achievement of certain performance milestones set by the Compensation Committee. These performance milestones include the following:

<u>Table of Contents</u> CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

Milestone #1—our Chief Executive Officer's annual goals, or CSFs, include various corporate-level strategic goals focused on financial results of operation, cost savings, gaining additional market share, introducing new products on specific schedules, implementing various operational and customer-facing systems as well as achieving certain organizational best practices ("CEO CSFs"). The CEO CSFs represent the action items that are most critical to the Company's short- and long-term success. Each individual goal is assigned a specific number of points and each goal has specific targets that are determined in advance and document what is required to achieve 100% of the goal and then scales down to a specific 0% point. The maximum number of points, or the "CSF score", that can be achieved for the CEO CSFs is 100 and there is no discretionary component to the score of the CEO CSFs as each goal is specific and measurable. In order for a participant to earn 100% of the shares underlying Milestone #1, our CEO must obtain 85 points or greater under the CEO CSFs and achievement then scales down linearly to 0% of shares earned if the CEO CSF score is less than 60 points.

Milestone #2—requires the Company to achieve a specific revenue amount during fiscal year 2015. In order for a participant to earn 100% of the RSUs underlying Milestone #2, the Company must achieve a specific revenue amount level in fiscal year 2015 which scales down linearly to 0% of the shares earned if the dollar value of the specific revenue amount is less than target.

Milestone #3—requires the participant to remain employed through January 30, 2016. 75% of Milestone #3 targeted PARS vest on January 30, 2015 and the remaining 25% will vest on January 30, 2016.

Both Milestones #1 and #2 will be multiplied by a Total Shareholder Return (TSR) Factor, for the applicable milestone performance period as compared to the performance of a Peer Group of Companies as detailed in our 2014 Proxy. The TSR factor which adjusts on a linear scale is .625 if Cypress is at the 10th or lower rank order percentile, 1.0 if Cypress is in the 40th and 60th rank percentile and 1.375 if Cypress is at the 90th or higher rank order percentile.

The payout amount for both Milestones #1 and #2 have the potential to earn above the targeted amount if the significantly outperform the target. In order to achieve greater than 100% of Milestone #1 a perfect score of 100 must be earned on the CEO CSFs. To achieve greater than 100% on Milestone #2 the Company must exceed the stretch revenue targets milestones by certain amounts. The potential amount that can be earned is adjusted on a linear scale and has a cap of 160% of the target.

Release of 2013 Performance-based Restricted Stock Shares

On February 27, 2014, the Committee approved the performance milestone achievements for fiscal year 2013. Before finalizing the 2013 PARS payouts, the Committee carefully considered the overall performance of the Company and concluded it was appropriate to exercise its right of negative discretion on the payout amounts earned. Of the total 3.9 million performance-based restricted stock units earned, 2.3 million were delivered and 1.6 million were forfeited due to negative discretion. The forfeited shares were returned to our equity pool.

NOTE 8. COMMITMENTS AND CONTINGENCIES

Operating Lease Commitments

We lease certain facilities and equipment under non-cancelable operating lease agreements that expire at various dates through fiscal 2018. Some leases include renewal options, which would permit extensions of the expiration dates at

rates approximating fair market rental values at the time of the extension.

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

As of March 30, 2014, future minimum lease payments under non-cancelable operating leases were as follows:

Fiscal Year	(In thousands)
2014 (remaining nine months)	\$5,365
2015	5,717
2016	3,548
2017	2,891
2018	345
2019 and thereafter	496
Total	\$18,362

Capital Lease

In 2011, we entered into a capital lease agreement which allows us to borrow up to \$35.0 million to finance the acquisition of certain manufacturing equipment. Assets purchased under the capital lease are included in "Property, plant and equipment, net" as manufacturing equipment and the amortization is included in depreciation. As of March 30, 2014, the gross value and net book value of manufacturing equipment purchased under a capital lease was approximately \$20.5 million and \$15.4 million, respectively. As of March 30, 2014, the total minimum lease payments under our capital leases amounted to approximately \$11.8 million.

Future minimum payments, by year and in the aggregate, under the capitalized lease consist of the following:

Fiscal Year	(In thousands)
2014 (remaining 9 months)	\$2,254
2015	2,936
2016	6,581
2017	599
2018	
Total minimum lease payments	12,370
Less: amount representing interest	542
Total	\$11,828

Product Warranties

We generally warrant our products against defects in materials and workmanship for a period of one year and that product warranty is generally limited to a refund of the original purchase price of the product or a replacement part. We estimate our warranty costs based on historical warranty claim experience. Warranty returns are recorded as an allowance for sales returns. The allowance for sales returns is reviewed quarterly to verify that it properly reflects the remaining obligations based on the anticipated returns over the balance of the obligation period.

The following table presents our warranty reserve activities:

	Three Month	s Ended
	March 30,	March 31,
	2014	2013
	(In thousands	s)
Beginning balance	\$2,628	\$3,360
Settlements made	(333) (151)
Provisions	333	151
Ending balance	\$2,628	\$3,360
Equity Investment Commitments		

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

As disclosed in Note 5, we have committed to purchase additional preferred stock from a company that works in the area of advanced battery storage. During the first fiscal quarter of 2014, our percentage ownership increased to over 20 percent. As of March 30, 2014, we currently own approximately 20.3% of the company. Our investment is now accounted for using the equity method of accounting. See Note 9 for additional disclosure related to the equity accounting method for this investment.

Subject to the attainment of certain milestones, we plan to potentially purchase additional preferred stock of approximately \$19 million in fiscal 2014 and actual amounts purchased could vary substantially. Litigation and Asserted Claims

Our seven-patent infringement case is currently pending against GSI's static random access memory ("SRAM") technology in the United Stated District Court for Northern California. We are seeking damages as well as injunctive relief in the case which has been assigned to Judge Tigar. Our initial infringement contentions on all seven patents have been filed in the case, discovery continues and we are currently working on the claim construction process. In defense of our claims, GSI has now submitted applications for inter-partes review with the PTO on five of our asserted patents. We believe strongly in the merits of our patent infringement claims, and intend to take the steps necessary to protect our intellectual property.

With respect to the civil antitrust case filed by GSI in the United States District Court for the Northern California, fact discovery is now complete and expert work has begun in the case. GSI's case, which only names Cypress as a defendant, accuses the QDR Consortium, which was comprised of several other semiconductor companies, of certain anti-competitive behavior. Aside from injunctive relief, GSI has made no specific monetary demand in the antitrust matter. Accordingly, the possible range of monetary loss that might be demanded in the future in the matter, if any, is unknown at this time. However, the case has been narrowed to any damages sustained between 2007-2011 and only with respect to possible lost sales on GSI's SigmaQuadIII product family. We believe strongly that we have meritorious defenses to the allegations set forth in the GSI civil antitrust complaint and we intend to defend ourselves vigorously in this matter.

With respect to the litigation stemming from our acquisition of Ramtron, both the Dent and the Weber shareholder litigation cases remain inactive. We have motions to dismiss pending in each of those cases. We believe strongly that these cases are without merit. As such, in the event either plaintiff chooses to take further action, we will defend ourselves vigorously. Because the case is at a very early stage and no specific monetary demand has been made, it is not possible for us to estimate the potential loss or range of potential losses for either case.

On December 11, 2012, LongPath Capital, LLC ("LongPath") filed an appraisal petition with the Court of Chancery in the State of Delaware in connection with our acquisition of Ramtron. Specifically, the petition seeks an appraisal of the fair value of the common stock shares held by LongPath, and an order that Ramtron pay such fair value, plus interest and attorney's fees. We believe LongPath's petition is without merit and we intend to defend this matter vigorously. We are currently engaged in the expert discovery phase of this case. Trial has been rescheduled by the court to October 2014. In May 2013, Plaintiff LongPath was paid the purchase price of \$3.10 per share, or approximately \$1.5 million. As a result, our potential exposure is limited to any premium on the purchase price that might be awarded by the court. The respective positions of the parties on valuation make it impossible for us to accurately estimate the potential exposure, if any, for this matter.

After extended licensing discussions were effectively abandoned by LG Electronics, Inc. ("LG") and Blackberry Limited/Blackberry Corporation ("Blackberry"), on August 29, 2013, we filed a patent infringement complaint against LG in the federal district court in the Northern District of California, accusing certain of their products of infringing six of our USB and Touch patents. We have filed our initial infringement contentions in the case, and are beginning discovery. The court has not yet set a date for the Markman hearing or the trial. We filed a second complaint in the Northern District of California with respect to the same six USB and Touch patents against Blackberry on September 10th. On November 4, 2013, Blackberry filed an answer to our complaint along with a counter-claim asserting two of their patents against us. Blackberry filed a second patent infringement complaint in the Northern District of Texas,

asserting two of its patents against us. We have reviewed all the asserted patents and are confident in our ability to defend ourselves. On January 31, 2014, we filed applications for inter-partes review by the PTO on both of the patents asserted in the Northern District of Texas case. Our motion to stay the Texas case was denied. Accordingly, absent an agreement between the parties, the case will move forward in the second fiscal quarter of this year when we expect to file counter-assertions. The California case against Blackberry has been reassigned to Judge Freeman, and the parties are awaiting a case schedule. Both Blackberry and Cypress are seeking unstated damages and injunctive relief in each of our respective cases. We believe strongly in the merits of our patent infringement claims, and intend to take the steps necessary to protect our intellectual property as well as the business interests of our non-infringing customers. On September 24, 2013, we filed a three-patent infringement case against Silego Technology, Inc. ("Silego") in federal district court in the Northern District of California. The parties have reached a settlement agreement in this matter which will result in the dismissal of this case.

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

We are currently a party to various other legal proceedings, employee-related claims, disputes and litigation arising in the ordinary course of business. Based on our own investigations, we believe the ultimate outcome of our current legal proceedings, individually and in the aggregate, will not have a material adverse effect on our financial position, results of operation or cash flows. However, because of the nature and inherent uncertainties of the litigation, should the outcome of these actions be unfavorable, our business, financial condition, results of operations or cash flows could be materially and adversely affected.

Indemnification Obligations

We are a party to a variety of agreements pursuant to which we may be obligated to indemnify another party to such agreements with respect to certain matters. Typically, these obligations arise in the context of contracts we have entered into, under which we customarily agree to hold the other party harmless against losses arising from a breach of representations and covenants or terms and conditions related to such matters as the sale and/or delivery of our products, title to assets sold, certain intellectual property claims, defective products, specified environmental matters and certain income taxes. In these circumstances, payment by us is customarily conditioned on the other party making a claim pursuant to the procedures specified in the particular contract, which procedures typically allow us to challenge the other party's claims and vigorously defend ourselves and the third party against such claims. Further, our obligations under these agreements may be limited in terms of time, amount or the scope of our responsibility and in some instances, we may have recourse against third parties for certain payments made under these agreements. It is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments we have made under these agreements have not had a material effect on our business, financial condition or results of operations. We believe that if we were to incur a loss in any of these matters, such loss would not have a material effect on our business, financial condition, cash flows or results of operations, although there can be no assurance of this. As of March 30, 2014, we had no reason to believe a loss exceeding amounts already recognized had been incurred.

NOTE 9. EQUITY METHOD INVESTMENT

Change in Accounting Principle

During the first quarter of fiscal 2014, we invested an additional \$4.0 million in a battery company. The additional investment in this company increased our ownership interest in the company's outstanding stock from 17.2% to 20.3% and required us to change from the cost method of accounting to the equity method of accounting for this investment. Under the equity method of accounting, we are required to record our interest in the company's reported net income or loss each reporting period. Additionally, we are required to present our prior period financial results to reflect the equity method of accounting from the date of the initial investment in the company which resulted in a \$3.0 million adjustment to retained earnings and a corresponding reduction to our investment. The results for the three months ended March 30, 2014 and March 31, 2013 include a charge of \$0.9 million and \$0.3 million respectively, recorded in Other Income and Expense which represents our portion of the losses incurred by the investee for the periods presented.

The following table lists the relevant captions from our statements of operations, as originally presented, and after the change in accounting principle:

<u>Table of Contents</u> CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)										
As previously presented	Q1'12	Q2'12	Q3'12	Q4'12	FY'12	Q1'13	Q2'13	Q3'13	Q4'13	FY'13
Net Income from Operations Interest and	(17,640)	5,148	15,047	(21,470)	(18,915)	(29,175)	(8,132)	(9,989)	(10,899)	(58,195)
other income (expense), net	334	1	(1,330)	(1,750)	(2,745)	483	2,119	427	(804)	2,225
Equity Impairment Net Income/Loss	(19,460)	4,977	14,332	(22,219)	(22,370)	(28,195)	3,766	(8,358)	(13,577)	(46,364)
EPS Basic Diluted	· ,	0.03 0.03	0.1 0.09	(0.15) (0.15)	. ,	. ,	0.03 0.02	· /	(0.09) (0.09)	(0.31) (0.31)
As adjusted Net Income from Operations Pro rata shar	(17,640)	5,148	15,047	(21,470)	(18,915)	(29,175)	(8,132)	(9,989)	(10,899)	(58,195)
of (loss) from equity investments	n(242)	(279)	(278)	(276)	(1,075)	(284)	(490)	(471)	(632)	(1,877)
Interest and other income (expense), net Equity Impairment	334	1	(1,330)	(1,750)	(2,745)	483	2,119	427	(804)	2,225
Net Income/Loss EPS	(19,702)	4,698	14,054	(22,495)	(23,445)	(28,479)	3,276	(8,829)	(14,209)	(48,241)
Basic Diluted Cumulative		0.03 0.03	0.10 0.09		. ,	. ,	0.02 0.02			(0.32) (0.32)
effect of change in retained earnings	(242)	(521)	(799)	(1,075)	(1,075)	(1,359)	(1,849)	(2,320)	(2,952)	(2,952)

NOTE 10. DEBT AND EQUITY TRANSACTIONS

Senior Secured Revolving Credit Facility

We have a \$300 million senior secured revolving credit facility ("Credit Facility") in which the borrowings are collateralized by substantially all assets of the Company. The financial covenants include the following conditions: 1) maximum senior secured leverage ratio of 2.50 to 1.00 through January 1, 2017 and 2.25 to 1.0 thereafter, 2) maximum total leverage ratio of 4.25 to 1.00 through January 3, 2015, 3.50 to 1.00 through January 1, 2017, and 3.00 to 1.00 thereafter, 3) minimum fixed charge coverage ratio of 1.00 to 1.00, and 4) minimum liquidity of at least \$100 million. At March 30, 2014, our remaining outstanding borrowings of \$227.0 million were recorded as part of long-term liabilities and are presented as "Long-term revolving credit facility" in the Condensed Consolidated Balance Sheet. As of March 30, 2014 and December 29, 2013 we were in compliance with all of the financial covenants under the Credit Facility.

Equipment Loans

In December 2011, we obtained equipment loans from a financial institution for an aggregate amount of approximately \$14.1 million which are collateralized by certain manufacturing equipment and bear interest of 3.15% to 3.18% per annum payable in 60 equal installments with the first installment due January 2012. Of the \$8.0 million outstanding balance as of March 30, 2014, approximately \$2.1 million was recorded as part of "Other current liabilities" in the Condensed Consolidated Balance Sheet.

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

The schedule of principal payments under our equipment loans is as follows:

Fiscal Year	(In thousands)
2014 (remaining nine months)	\$2,127
2015	2,915
2016	3,003
Total	\$8,045

\$400 Million Stock Buyback Program:

For the three months ended March 30, 2014, repurchases made under this program were immaterial. Since we announced our \$400 million stock buyback program in September 2011 through the end of the first quarter of fiscal 2014, we used approximately \$316.7 million from this program to repurchase approximately 23.6 million shares at an average share price of \$13.43. As of March 30, 2014, the total remaining dollar amount of shares that may be repurchased under the program was approximately \$83.3 million.

Dividends

On February 28, 2014, our Board of Directors approved a cash dividend of \$0.11 per share payable to holders of record of our common stock at the close of business day on March 27, 2014. This cash dividend was paid on April 17, 2014 and totaled approximately \$17.3 million which was accrued for in the first quarter of fiscal 2014 and shown as "Dividends payable" in the Condensed Consolidated Balance Sheet as of March 30, 2014.

NOTE 11. ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of accumulated other comprehensive loss were as follows:

	Net unrealized gains (loss) on investments		Cumulative translation adjustment and other	Accumulated of comprehensive loss (income)	
Balance as of December 29,2013	\$(183)	\$6	\$ (177)
Other comprehensive income attributable to Cypress	(5)		(5)
Balance as of March 30, 2014	\$(188)	\$6	\$ (182)

(1) For defined benefit pension items, please see Note 16, Employee Benefit Plan, in our Consolidated Financial Statements, in our Annual Report on Form 10-K for the year ended December 29, 2013.

NOTE 12. FOREIGN CURRENCY DERIVATIVES

The aggregate notional and fair value of outstanding forward contracts to hedge the risks associated with foreign currency denominated assets and liabilities as of December 29, 2013 was not material to our consolidated financial statements. There were no outstanding forward contracts as of March 30, 2014.

NOTE 13. INCOME TAXES

Our income tax benefit was \$4.5 million for the three months ended March 30, 2014 compared to a provision of \$0.1 million for the three months ended March 31, 2013. The tax benefit/provision for the first quarter of 2014 was primarily attributable to a release of previously accrued taxes and interest for the 2008 Philippines BIR examination and due to the expired statutes of limitations in foreign jurisdictions, offset by non-U.S. taxes on income earned in foreign jurisdictions. The tax provision for the first quarter of fiscal 2013 was primarily attributable to non-U.S. taxes on income earned in foreign jurisdictions, partially offset by release of previously accrued income taxes due to expired

statute of limitations in foreign jurisdictions.

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

Unrecognized Tax Benefits

As of March 30, 2014 and December 29, 2013, the amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate totaled \$13.2 million and \$17.6 million, respectively

Management believes events that could occur in the next 12 months and cause a material change in unrecognized tax benefits include, but are not limited to, the following:

completion of examinations by the U.S. or foreign taxing authorities; and

expiration of statute of limitations on our tax returns.

The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses our tax positions in light of legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which we do business. We believe it is possible that we may recognize approximately \$1.8 million to \$2.5 million of our existing unrecognized tax benefits within the next twelve months as a result of the lapse of statutes of limitations and the resolution of agreements with domestic and various foreign tax authorities.

Classification of Interest and Penalties

Our policy is to classify interest and penalties, if any, as components of the income tax provision in the Condensed Consolidated Statements of Operations. As of March 30, 2014 and December 29, 2013, the amount of accrued interest and penalties totaled \$2.8 million and \$5.8 million, respectively.

NOTE 14. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended		
	March 30,	March 31,	
	2014	2013	
	(In thousands,	except per-share	•
	amounts)		
Net loss attributable to Cypress	\$(7,934) \$(28,479)
Weighted-average common shares	154,572	145,689	
Weighted-average diluted shares	154,572	145,689	
Net loss per share—basic	\$(0.05) \$(0.20)
Net loss per share—diluted	\$(0.05) \$(0.20)

For the three months ended March 30, 2014, approximately 8.9 million weighted average potentially dilutive securities were excluded in the computation of diluted net income (loss) per share because their effect would have been anti-dilutive.

For the three months ended March 31, 2013, approximately 7.4 million weighted average potentially dilutive securities were excluded in the computation of diluted net income (loss) per share because their effect would have been anti-dilutive.

NOTE 15. SEGMENT, GEOGRAPHICAL AND CUSTOMER INFORMATION

Segment Information

We design, develop, manufacture and market a broad range of programmable system solutions for various markets including consumer, computation, data communications, automotive and industrial. We evaluate our reportable business segments in accordance with the accounting guidance. We operate in the following four reportable business segments:

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

Business Segments	Description
PSD: Programmable Systems Division	A division focusing primarily on our PSoC [®] and PSoC-based products. This business segment focuses on (1) the PSoC platform family of devices including PSoC 1, PSoC 3, PSoC 4 and PSoC 5 and all derivatives, (2) PSoC-based user interface products such as CapSense [®] touch-sensing and TrueTouch [®] touchscreen products, (3) automotive products and (4) certain legacy product lines.
MPD: Memory Products Division	A division that will continue to focus on our SRAM, FRAM and non-volatile business units and general-purpose programmable clocks.
DCD: Data Communications Division	A division focusing on USB controllers and WirelessUSB TM peripheral controllers, also offering module solutions including Trackpads and Ovation TM Optical Navigation Sensors.
ETD: Emerging Technologies Division	Our "startup" division includes AgigA Tech Inc. and Deca Technologies Inc., both majority-owned subsidiaries of Cypress. ETD also includes our foundry business and other development-stage activities.

The following tables set forth certain information relating to the reportable business segments:

Revenue

Revenue			
	Three Months Ended		
	March 30,	March 31,	
	2014	2013	
	(In thousands)		
Programmable Systems Division	\$69,347	\$65,505	
Memory Products Division	81,323	82,229	
Data Communications Division	15,590	22,747	
Emerging Technologies Division	4,023	2,247	
Total revenue	\$170,283	\$172,728	
Loss before Income Taxes			
	Three Months Ended		
	March 30,	March 31,	
	2014	2013	
	(In thousands)		
Programmable Systems Division	\$(8,667) \$(14,850)
Memory Products Division	28,807	26,003	
Data Communications Division	(3,790) (2,283)
Emerging Technologies Division	(3,860) (4,592)
Unallocated items:			

Stock-based compensation	(16,822) (12,437)
Amortization of acquisition-related intangibles	(5,274) (2,894)
Restructuring charges	1,014	(11,440)
Changes in value of deferred compensation plan	(747) (674)
Impairment of assets and other	(3,447) (5,809)
Loss before income taxes	\$(12,786) \$(28,976)

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

Depreciation

	Three Months	Three Months Ended	
	March 30, March		
	2014	2013	
	(In thousands)		
Programmable Systems Division	\$3,448	\$3,490	
Memory Products Division	3,911	4,309	
Data Communications Division	808	1,237	
Emerging Technologies Division	1,318	1,319	
Total depreciation	\$9,485	\$10,355	

Geographical Information

The following table presents our revenues by geographical locations:

	Three Months Ended		
	March 30,	March 31,	
	2014	2013	
	(In thousands		
United States	\$19,254	\$21,158	
Europe	23,842	18,640	
Asia:			
China	71,884	68,986	
South Korea	19,288	25,821	
Japan	15,335	14,531	
Rest of the World	20,680	23,592	
Total revenue	\$170,283	\$172,728	

Property, plant and equipment, net, by geographic locations were as follows:

	As of	
	March 30,	December 29,
	2014	2013
	(In thousands)	1
United States	\$143,419	\$152,628
Philippines	89,665	59,873
Other	20,150	46,084
Total property, plant and equipment, net	\$253,234	\$258,585

We track our assets by physical location. Although management reviews asset information on a corporate level and allocates depreciation expense by segment, our chief operating decision maker does not review asset information on a segment basis.

Table of Contents CYPRESS SEMICONDUCTOR CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued) (Unaudited)

Customer Information

Outstanding accounts receivable from two of our distributors, accounted for 25% and 13% of our consolidated accounts receivable as of March 30, 2014. Outstanding accounts receivable from three of our distributors, accounted for 17%, 12% and 11% of our consolidated accounts receivable as of December 29, 2013.

Revenue generated through two of our distributors accounted for 12% and 10% of our consolidated revenue for the three months ended March 30, 2014. Revenue to one end customer purchases our products both from our distributors and directly from us. Shipments to this end customer accounted for 11% of our consolidated revenue for the three months ended March 30, 2014 and this end customer purchases our products both from our distributors and directly from us.

Revenue generated through three of our distributors accounted for 11%, 11% and 11% of our consolidated revenue for the three months ended March 31, 2013. Shipments made by our distributors to one end customer during the three months ended March 31, 2013 accounted for 12% of our consolidated revenues.

Tables of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Management's Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, which are discussed in the "Forward-Looking Statements" section under Part I of this Quarterly Report on Form 10-Q.

EXECUTIVE SUMMARY

General

Cypress Semiconductor Corporation ("Cypress") delivers high-performance, mixed-signal, programmable solutions that provide customers with rapid time-to-market and exceptional system value. Cypress offerings include our flagship PSoC[®] 1, PSoC 3, PSoC 4, and PSoC 5 programmable system-on-chip families. Cypress is a world leader in capacitive user interface solutions including CapSense[®] touch sensing, TrueTouch[®] touchscreens, and trackpad solutions for notebook PCs and peripherals. Cypress is also a significant participant in Universal Serial Bus (USB) controllers, which enhance connectivity and performance in a wide range of consumer and industrial products. Cypress is also the world leader in static random access memory (SRAM) and nonvolatile RAM memories. Cypress serves numerous major markets, including consumer, mobile handsets, computation, data communications, automotive, industrial, and military.

We evaluate our reportable business segments in accordance with the accounting guidance. We operate in the following four reportable business segments:

Business Segments	Description
MPD: Memory Products Division	MPD focuses on static random access memory (SRAM), nonvolatile RAMs and general-purpose programmable clocks.
DCD: Data Communications Division	DCD focuses on USB controllers and WirelessUSB TM peripheral controllers, also offering module solutions including Trackpads and Ovation TM Optical Navigation Sensors.
PSD: Programmable Systems Division	PSD focuses primarily on our PSoC® programmable system-on-chip and PSoC-based products. This business segment focuses on (1) the PSoC platform family of devices including PSoC 1, PSoC 3, PSoC 4 and PSoC 5, and all derivatives, (2) PSoC-based user interface products such as CapSense® touch-sensing and TrueTouch® touchscreen products, and (3) automotive products.
ETD: Emerging Technologies Division	Our "startup" division includes AgigA Tech Inc. and Deca Technologies Inc., both majority-owned subsidiaries of Cypress. ETD also includes our foundry business and other development-stage activities.

Manufacturing Strategy

Our core manufacturing strategy—"flexible manufacturing"—combines capacity from foundries with output from our internal manufacturing facilities. This initiative is intended to allow us to meet rapid swings in customer demand while lessening the burden of high fixed costs, a capability that is particularly important in high-volume consumer markets that we serve with our leading programmable product portfolio.

Results of Operations

Revenues

The following table summarizes our consolidated revenues by segments:

	March 30, 2014	March 31, 2013	
	(In thousands)		
Programmable Systems Division	\$69,347	\$65,505	
Memory Products Division	81,323	82,229	
Data Communications Division	15,590	22,747	
Emerging Technologies Division	4,023	2,247	
Total revenue	\$170,283	\$172,728	

Three Months Ended

Programmable Systems Division:

Revenues from the Programmable Systems Division increased by \$3.8 million in the first quarter of fiscal 2014, approximately 6% compared to the same prior-year periods primarily attributable to an increase in sales of our TrueTouch[®] touchscreen and automotive products. The increases were partially offset by a decrease in sales of certain legacy communication products.

Memory Products Division:

Revenues from the Memory Products Division decreased by approximately \$0.9 million in the first quarter of fiscal 2014 or (1)% compared to the same prior-year period primarily attributable to a decline in sales of our SRAMs, partially offset by an increase in revenue of our non-volatile memory products.

Data Communications Division:

Revenues from the Data Communications Division decreased by \$7.2 million in the first quarter of fiscal 2014, or approximately 31%, compared to the same prior-year period primarily due to the decreases in sales of our older USB-related products.

Emerging Technologies Division:

Revenues from the Emerging Technologies Division increased by \$1.8 million in the first quarter of fiscal 2014, or 79%, compared to the same prior-year period primarily due to the overall increase in demand as certain of our Emerging Technologies companies had design wins that moved into production.

Cost of Revenues/Gross Margins

	Three Months Ended		
	March 30, 2014	March 31, 2	2013
	(In thousands)		
Cost of revenues	\$92,561	\$93,682	
Gross margin	45.6	% 45.8	%
Gross margin percentage decreased slightly in the first quarter of fiscal 201	14 primarily due to pro	duct and custon	ner

Gross margin percentage decreased slightly in the first quarter of fiscal 2014 primarily due to product and customer mix.

Research and Development ("R&D") Expenses

	Three Months Ended			
	March 30, 2014		March 31, 2013	3
	(In thousands)			
R&D expenses	\$45,330		\$49,330	
As a percentage of revenues	26.6	%	28.6	%

Tables of Contents

R&D expenditures decreased by \$4.0 million in the first quarter of fiscal 2014 compared to the same prior-year period. The decrease was primarily attributable to a \$1.2 million one-time charge for the write-off of tools we purchased as part of the acquisition of Ramtron in the first quarter of 2013, a \$0.9 million decrease in consulting fees, a \$0.6 million decrease in headcount-related expenses, a \$0.6 million decrease in outside services and a \$0.5 million decrease in variable bonus-related expense. The decreases were partially offset by a \$2.2 million increase in stock-based compensation. As a percentage of revenues, R&D expenses were lower in the first quarter of fiscal 2014 driven by the decrease in total revenues in the same prior-year period.

Selling, General and Administrative ("SG&A") Expenses

	Three Months Ende	Three Months Ended		
	March 30, 2014 March 3		h 31, 2013	
	(In thousands)			
SG&A expenses	\$42,609	\$45,442		
As a percentage of revenues	25.0	% 26.3	%	
		-		

SG&A expenses decreased by \$2.8 million in the first quarter of fiscal 2014 compared to the same prior-year period. The decrease was primarily attributable to a \$4.9 million decrease in headcount-related expenses which was driven by a company-wide effort to reduce costs, a \$1.0 million decrease in variable bonus-related expense and a \$0.9 million decrease in deferred compensation expense. These decreases were partially offset by an increase in stock-based compensation expense of \$3.5 million due to an increase in certain performance-based awards and an increase in legal expenses of \$1.1 million. As a percentage of revenues, SG&A expenses were lower in the first quarter of fiscal 2014 driven by a company-wide effort to reduce overall operating expenses.

Restructuring

For the three months ended March 30, 2014 we recorded a benefit arising from restructuring related items of \$(1.0) million, compared to a restructuring charge of \$11.4 million incurred during the three months ended March 31, 2013. The benefit for the period primarily resulted from the gain on the sale of a previously restructured asset. The determination of when we accrue for severance and benefits costs, and which accounting standard applies, depends on whether the termination benefits are provided under a one-time benefit arrangement or under an on-going benefit arrangement.

The following table summarizes the restructuring charges recorded in the Condensed Consolidated Statements of Operations:

	Three Months Ended		
	March 30, March		
	2014	2013	
	(In thousands)		
Personnel costs	\$(154,000) \$4,157,000	
Impairment of property, plant and equipment	—	6,698,000	
Other	(281,000) 585,000	
Gain on sale of held-for-sale assets	(579,000) —	
Total restructuring charges	\$(1,014,000) \$11,440,000	

A summary of the restructuring activities related to personnel costs, which are primarily in the U.S. is summarized as follows:

	(In thousands)		
Balance as of December 29 2013	\$4,158		
Provision (release)	(154)		
Cash payments	(1,311)		
Balance as of March 30, 2014	2,693		

Tables of Contents

The restructuring liability as of March 30, 2014 related primarily to personnel costs and is expected to be paid out within the next twelve months.

During fiscal 2013, we implemented a restructuring plan to reduce operating expenses as part of our 2013 corporate priorities. The plan included the termination of employees and the disposal of certain equipment located in our Bloomington, Minnesota facility. During the first quarter of fiscal 2014, we did not record any new restructuring charges. For the first fiscal quarter of 2013, we recorded restructuring charges of \$11.0 million related to the Fiscal 2013 Restructuring Plan of which \$6.7 million was related to property, plant and equipment, \$3.8 million was related to personnel costs and \$0.5 million was mainly related to the amounts payable upon the termination of agreements with certain distributor representatives.

During the first quarter of fiscal 2014, we did not record any new restructuring charges under a restructuring plan which we first announced in fiscal 2011 ("Fiscal 2011/2012 Restructuring Plan"). This plan allowed us to continue to allocate and align our resources to the business units that we expect will drive future development and revenue growth. For the first fiscal quarter of 2013, we recorded restructuring charges of \$0.4 million. Assets Held-For-Sale

During the first quarter of 2013, we incurred a \$6.0 million charge to write down certain equipment to the then-current fair value of \$2.3 million. The net book value of these assets was classified as held-for-sale and included in "Other current assets" in the Condensed Consolidated Balance Sheet as of December 29, 2013. In the first fiscal quarter of 2014, we sold this equipment and recorded a gain on the sale of \$0.6 million, net of selling costs, as a credit to restructuring costs in the Condensed Consolidated Statement of Operations. Income Taxes

Our income tax benefit was \$4.5 million for the three months ended March 30, 2014 and tax expense was \$0.1 million for the three months ended March 31, 2013. The tax benefit/provision for the first quarter of 2014 was primarily attributable to a release of previously accrued taxes and interest for the 2008 Philippines BIR examination and due to the expired statutes of limitations in foreign jurisdictions, offset by non-U.S. taxes on income earned in foreign jurisdictions, partially offset by release of previously accrued taxes and income taxes due to expired statute of limitations in foreign jurisdictions.

LIQUIDITY AND CAPITAL RESOURCES

The following table summarizes information regarding our cash and investments and working capital:

	As of	
	March 30, 2014	December 29, 2013
	(In thousands)	
Cash and cash equivalents	\$103,644	\$86,009
Short-term investments	7,881	18,453
Total cash, cash equivalents and short-term investments	\$111,525	\$104,462
Total current assets	\$343,427	\$319,713
Total current liabilities	331,045	305,842
Working capital	\$12,382	\$13,871

Key Components of Cash Flows

	Three Months Ended			
	March 30, 2014 March 3		31, 2013	
	(In thousands)			
Net cash provided by operating activities	\$25,191	\$8,265		
Net cash provided by (used in) investing activities	\$2,063	\$(895)	

Net cash used in financing activities

Three Months Ended March 30, 2014

During the three months ended March 30, 2014, cash and cash equivalents increased by approximately \$17.6 million primarily due to the cash we generated from our operating and investing activities of approximately \$25.2 million and \$2.1 million, respectively. This increase was partially offset by the \$9.6 million of cash we used in our financing activities, principally related to our dividend payment of \$16.9 million.

Operating Activities

The \$25.2 million in cash generated from our operating activities during the three months ended March 30, 2014 was primarily due to \$22.4 million in net favorable non-cash adjustments to our net loss, an increase in deferred margin on sales to distributors and accounts payable and other liabilities, and decreases in inventories and other assets, partially offset by an increase in accounts receivable.

The key changes in our working capital as of March 30, 2014 compared to December 29, 2013 were as follows: Total cash, cash equivalents and short-term investments increased by \$17.6 million primarily due to issuance of common shares and the sale and maturities of certain investments.

Accounts receivable increased by \$37.1 million primarily due to an increase in distributor shipments in the latter-half of the quarter.

Deferred margin on sales to distributors increased by \$19.1 million due to an increase in distributor inventory.

Inventories decreased by \$12.2 million compared to December 29, 2013 due in part to reduced wafer starts to manage our production and an increase in distributor shipments in the latter-half of the quarter.

Investing Activities

During the three months ended March 30, 2014, we generated approximately \$2.1 million of cash from our investing activities primarily due to \$10.5 million the sales or maturities of investments and proceeds from the sale of restructured equipment totaling \$3.2 million, partially offset by \$5.6 million of cash used for property and equipment expenditures, \$5.0 million cash paid as an additional investment in certain non-marketable equity securities and a \$1.1 million cash distribution for our deferred compensation plan.

Financing Activities

During the three months ended March 30, 2014, we used approximately \$9.6 million of cash from our financing activities primarily related to a \$16.9 million dividend payment and \$1.3 million used to repay equipment leases and loan. These decreases were partially offset by net proceeds from the issuance of common shares under our employee stock plans of \$8.8 million.

Liquidity and Contractual Obligations

Stock Buyback Program

On September 20, 2011, our Board of Directors authorized a \$400 million stock buyback program. For the three months ended March 30, 2014, repurchases made under this program were immaterial. As of March 30, 2014, the total remaining dollar value of the shares that may be repurchased under the program was approximately \$83.3 million. Contractual Obligations

The following table summarizes our contractual obligations as of March 30, 2014:

	Total	2014	2015 and 2016	2017 and 2018	After 2018
	(In thousands))			
Purchase obligations (1)	\$55,019	\$48,945	\$6,074	\$—	\$—
Operating lease commitments	18,362	5,365	9,265	3,236	496
Capital lease commitments	12,370	2,254	9,517	599	
Patent license fee commitments (2)	5,880		5,880		
Total contractual obligations	\$91,631	\$56,564	\$30,736	\$3,835	\$496

Purchase obligations primarily include non-cancelable purchase orders for materials, services, manufacturing (1)equipment, building improvements and supplies in the ordinary course of business. Purchase obligations are defined as

enforceable agreements that are legally binding on us and that specify all significant terms, including quantity, price and timing.

On April 30, 2012, we entered into a patent license agreement whereby we paid a total patent license fee of \$14.0 (2)million in fiscal 2012 and committed to pay another \$5.9 million on or before April 30, 2016 representing fees for future purchases of patents and patent related services.

As of March 30, 2014, our unrecognized tax benefits were \$4.5 million, which were classified as long-term liabilities. We believe it is possible that we may recognize approximately \$1.8 million to \$2.5 million of our existing unrecognized tax benefits within the next twelve months as a result of the lapse of statutes of limitations and the resolution of agreements with domestic and various foreign tax authorities.

Equity Investment Commitments

As disclosed in Note 5, we have committed to purchase additional preferred stock from a company that operates in the area of advanced battery storage. During the three months ended March 30, 2014, we purchased \$4.0 million of preferred stock which was recorded as part of our investments in non-marketable securities. Subject to the attainment of certain milestones, we plan to potentially purchase additional preferred stock of approximately \$19 million in fiscal 2014 and actual amounts purchased could vary substantially.

Capital Resources and Financial Condition

Our long-term strategy is to maintain a minimum amount of cash and cash equivalents for operational purposes and to invest the remaining amount of our cash in interest-bearing and highly liquid cash equivalents and debt securities, payments of regularly scheduled cash dividends, the repayment of our short-term debt, and the purchase of our stock through our stock buyback program. As of March 30, 2014, in addition to \$103.6 million in cash and cash equivalents, we had \$7.9 million invested in short-term investments for a total cash, cash equivalents and short-term investment position of \$111.5 million that is available for use in our current operations.

As of March 30, 2014, approximately 21% of our cash, cash equivalents and available-for-sale investments are held in offshore funds. While these amounts are primarily invested in U.S. dollars, a portion is held in foreign currencies. All offshore balances are exposed to local political, banking, currency control and other risks. In addition, these amounts, if repatriated may be subject to tax and other transfer restrictions.

We believe that liquidity provided by existing cash, cash equivalents and available-for-sale investments and our borrowing arrangements will provide sufficient capital to meet our requirements for at least the next twelve months. However, should prevailing economic conditions and/or financial, business and other factors beyond our control adversely affect the estimates of our future cash requirements; we could be required to fund our cash requirements by alternative financing. There can be no assurance that additional financing, if needed, would be available on terms acceptable to us or at all. In addition we may choose at any time to raise additional capital or debt to strengthen our financial position, facilitate growth, enter into strategic initiatives including the acquisition of other companies and provide us with additional flexibility to take advantage of other business opportunities that arise. Non-GAAP Financial Measures

Regulation G, conditions for use of Non-Generally Accepted Accounting Principles ("Non-GAAP") financial measures, and other SEC regulations define and prescribe the conditions for use of certain Non-GAAP financial information. To supplement our condensed consolidated financial results presented in accordance with GAAP, we use Non-GAAP financial measures which are adjusted from the most directly comparable GAAP financial measures to exclude certain items, as described below. Management believes that these Non-GAAP financial measures reflect an additional and useful way of viewing aspects of our operations that, when viewed in conjunction with our GAAP results, provide a more comprehensive understanding of the various factors and trends affecting our business and operations. Non-GAAP financial measures used by us include gross margin, research and development expenses, selling, general and administrative expenses, operating income or loss, net income or loss and basic and diluted net income or loss per share.

Our Non-GAAP measures primarily exclude stock-based compensation, acquisition-related charges, impairments to goodwill, gain or losses on divestiture, investment-related gains and losses, discontinued operations, restructuring costs and other special charges and credits. Management believes these Non-GAAP financial measures provide

meaningful supplemental information regarding our strategic and business decision making, internal budgeting, forecasting and resource allocation processes. In addition, these Non-GAAP financial measures facilitate management's internal comparisons to our historical operating results and comparisons to competitors' operating results.

Tables of Contents

We use each of these Non-GAAP financial measures for internal managerial purposes, when providing our financial results and business outlook to the public, to facilitate period-to-period comparisons and to formulate our formula driven cash bonus plan and any milestone based stock awards. Management believes that these Non-GAAP measures provide meaningful supplemental information regarding our operational and financial performance of current and historical results. Management uses these Non-GAAP measures for strategic and business decision making, internal budgeting, forecasting and resource allocation processes. In addition, these Non-GAAP financial measures facilitate management's internal comparisons to our historical operating results and comparisons to competitors' operating results.

The following table shows our Non-GAAP financial measures:

	Three Months Ended		
	March 30, 2014 March 31, 2013		
	(In thousands, except per share		
	amounts)		
Non-GAAP gross margin	\$85,722	\$87,515	
Non-GAAP research and development expenses	\$37,723	\$41,947	
Non-GAAP selling, general and administrative expenses	\$33,784	\$38,996	
Non-GAAP operating income	\$14,216	\$6,572	
Non-GAAP net income attributable to Cypress	\$11,975	\$4,579	
Non-GAAP net income per share attributable to Cypress—diluted \$0.07 \$0.0		\$0.03	

We believe that providing these Non-GAAP financial measures, in addition to the GAAP financial results, are useful to investors because they allow investors to see our results "through the eyes" of management as these Non-GAAP financial measures reflect our internal measurement processes. Management believes that these Non-GAAP financial measures enable investors to better assess changes in each key element of our operating results across different reporting periods on a consistent basis and provides investors with another method for assessing our operating results in a manner that is focused on the performance of our ongoing operations.

CYPRESS SEMICONDUCTOR CORPORATION RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES (In thousands, except per-share data) (Unaudited)

	Three Months Ended		
	March 30, 2014	March 31, 2013	
GAAP gross margin	\$77,722	\$79,046	
Stock-based compensation expense	2,251	3,618	
Changes in value of deferred compensation plan	218	422	
Acquisition-related expenses	2,967	122	
Impairment of assets and other	2,564	4,307	
Non-GAAP gross margin	\$85,722	\$87,515	
GAAP research and development expenses	\$45,330	\$49,330	
Stock-based compensation expense	(7,183) (4,967)	
Acquisition-related expenses		(815)	
Changes in value of deferred compensation plan	(424) (207)	
Impairment of assets and other		(1,394)	
Non-GAAP research and development expenses	\$37,723	\$41,947	
GAAP selling, general and administrative expenses	\$42,609	\$45,442	
Stock-based compensation expense	(7,388) (3,852)	
Changes in value of deferred compensation plan	(964) (1,861)	
Acquisition-related expenses	(473) (556)	
Impairment of assets and other		(177)	
Non-GAAP selling, general and administrative expenses	\$33,784	\$38,996	
GAAP operating income (loss)	\$(11,036) \$(29,175)	
Stock-based compensation expense	16,822	12,437	
Changes in value of deferred compensation plan	1,606	3,098	
Acquisition-related expenses	5,274	2,894	
Impairment of assets and other	2,564	5,878	
Restructuring charges	(1,014) 11,440	
Non-GAAP operating income	\$14,216	\$6,572	
GAAP net income (loss) attributable to Cypress	\$(7,934) \$(28,479)	
Stock-based compensation	16,822	12,437	
Changes in value of deferred compensation plan	5,274	674	
Acquisition-related expenses	747	2,894	
Impairment of assets and other	2,564	5,525	
Restructuring charges	(1,014) 11,440	
Tax and tax-related items	(5,367) (196)	
Investment-related gains/losses	883	284	
Non-GAAP net income attributable to Cypress	\$11,975	\$4,579	
GAAP net income (loss) per share attributable to Cypress-diluted	(0.05) \$(0.20)	
Stock-based compensation expense and other	0.10	0.08	
Acquisition-related expenses	0.03	0.02	
Changes in value of deferred compensation plan	_	0.01	
Impairment of assets and other	0.02	0.04	
Restructuring charges	(0.01) 0.07	
Tax and tax-related items	(0.03) —	
Investment-related gains/losses	0.01		

Non-GAAP share count adjustment	_	0.01
Non-GAAP net income attributable to Cypress-diluted	\$0.07	\$0.03

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Interest Rate Risks

Our investment portfolio consists of a variety of financial instruments that exposes us to interest rate risk, including, but not limited to, money market funds, commercial paper and corporate securities. These investments are generally classified as available-for-sale and, consequently, are recorded on our balance sheets at fair market value with their related unrealized gain or loss reflected as a component of accumulated other comprehensive income in stockholders' equity. Due to the relatively short-term nature of our investment portfolio, we do not believe that an immediate 10% increase in interest rates would have a material effect on the fair market value of our portfolio. Since we believe we have the ability to liquidate this portfolio, we do not expect our operating results or cash flows to be materially affected to any significant degree by a sudden change in market interest rates on our investment portfolio. Foreign Currency Exchange Risk

We operate and sell products in various global markets and purchase capital equipment using foreign currencies but predominantly the U.S. dollar. As a result, we are exposed to risks associated with changes in foreign currency exchange rates. Changes in exchange rates between foreign currencies and the U.S. dollar may adversely affect our operating margins. For example, when foreign currencies appreciate against the U.S. dollar, inventory and expenses denominated in foreign currencies become more expensive. An increase in the value of the U.S. dollar relative to foreign currencies could make our products more expensive for international customers, thus potentially leading to a reduction in demand, and therefore in our sales and profitability. Furthermore, many of our competitors are foreign companies that could benefit from such a currency fluctuation, making it more difficult for us to compete with those companies. We cannot predict the impact of future exchange rate fluctuations on our business and results of operations.

We analyzed our foreign currency exposure, including our hedging strategies, to identify assets and liabilities denominated in other currencies. For those assets and liabilities, we evaluated the effects of a 10% shift in exchange rates between those currencies and the U.S. dollar. We have determined that there would be an immaterial effect on our results of operations from such a shift.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain "disclosure controls and procedures," as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q and subject to the foregoing, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three month period ended March 30, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The information required by this item is included in Note 8 of Notes to Condensed Consolidated Financial Statements under Item 1, Part 1 of this Quarterly Report on Form 10-Q and is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Other than the update to the risk factor below, there are no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 29, 2013.

We utilize debt financing and such indebtedness could adversely affect our business, financial condition, results of operations, earnings per share and our ability to meet our payment obligations.

We routinely incur indebtedness to finance our operations and from time to time we have significant amounts of outstanding indebtedness and substantial debt service requirements. On October 17, 2013, we amended our senior secured revolving credit facility with a group of lenders led by Morgan Stanley Senior Funding, Inc., to reduce the amount of the facility from \$430 to \$300 million. The credit facility contains customary affirmative, negative and financial covenants, including a maximum senior secured leverage ratio, a maximum total leverage ratio, minimum fixed charge coverage ratio, and a minimum liquidity of at least \$100 million. Our ability to meet our payment and other obligations and covenants under our indebtedness depends on our ability to generate significant cash flow. This, to some extent, is subject to general economic, financial, competitive, legislative and regulatory factors as well as other factors that are beyond our control. There is no assurance that our business will generate cash flow from operations, or that future borrowings will be available to us under our existing or any amended credit facilities or otherwise, in an amount sufficient to enable us to meet payment obligations under indebtedness we may under take from time to time. If we are not able to generate sufficient cash flow to service our debt obligations, we may need to refinance or restructure our debt, sell assets, reduce or delay capital investments, or seek to raise additional capital. If we are unable to implement one or more of these alternatives, we may not be able to meet our payment obligations under any indebtedness we owe. As of March 30, 2014, our outstanding debt included \$227 million related to our recent credit facility, \$11.8 million in capital leases, and approximately \$8.0 million in equipment loans. See Note 10 for more information on our Senior Secured Revolving Credit Facility and equipment loans.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ISSUER PURCHASES OF EQUITY SECURITIES

On September 20, 2011, our Board of Directors (the "Board") authorized a \$400 million stock buyback program. The program allows us to purchase our common stock or enter into equity derivative transactions related to our common stock. The timing and actual amount expended with the new authorized funds will depend on a variety of factors including the market price of our common stock, regulatory, legal, and contractual requirements, other uses of cash, and other market factors. The program does not obligate us to repurchase any particular amount of common stock and may be modified or suspended at any time at the discretion of our Board. As of March 30, 2014, the total remaining dollar amount of shares that may be repurchased under the program was approximately \$83.3 million.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES None.

ITEM 4. MINE SAFETY DISCLOSURES Not applicable.

ITEM 5. OTHER INFORMATION

Quarterly Executive Incentive Payments

There were no performance incentive payments earned by our executive officers in accordance with the terms of our Key Employee Bonus Plan (the "KEBP") and the Performance Bonus Plan (the "PBP") for the first quarter and the annual portion of fiscal 2014.

ITEM 6. EXHIBITS

		Incorporated by Reference			
Exhibit Number	Description	Form	Filing Date	File No.	Filed Herewith
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				Х
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				Х
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				Х
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				Х
101.INS*	XBRL Instance Document.				
101.SCH*	XBRL Taxonomy Extension Schema Document.				
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.				
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.				
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.				
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.				
* VDDI /E	Artansible Pusiness Deporting Language) information is furnic	had and	t not filed or a	part of a raci	stration

* XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYPRESS SEMICONDUCTOR CORPORATION

Date: May 2, 2014

By: /s/ BRAD W. BUSS Brad W. Buss Executive Vice President, Finance and Administration and Chief Financial Officer

EXHIBIT INDEX

		Incorporated by Reference			
Exhibit Number	Description	Form	Filing Date	File No.	Filed Herewith
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				Х
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				Х
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	,			Х
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	,			Х
101.INS*	XBRL Instance Document.				
101.SCH*	XBRL Taxonomy Extension Schema Document.				
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.				
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.				
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.				
101.PRE* * XBRL (I	XBRL Taxonomy Extension Presentation Linkbase Document. Extensible Business Reporting Language) information is furnis	shed and	d not filed or a	a part of a reg	istration
	or prospectus for purposes of sections 11 or 12 of the Securities				

statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.